Skip to content
drillr.ai
Sign up

688317.SH

之江生物

SSE · Healthcare · Biotechnology · CN

CNY 17.17
−2.99%
Ask drillr

  • Aug 27, 2026, 08:08 UTC

    ZhiJiang Bio announced its 2026 first-half results, reporting a net loss of 40.5894 million yuan, compared with a loss of 9.851 million yuan in the same period of 2025.

    Source:

  • Aug 19, 2026, 09:10 UTC

    Zhi Jiang Bio announced that its monkeypox virus nucleic acid detection kit (fluorescent PCR method) obtained a Class III medical device registration certificate from China's NMPA, valid from August 17, 2026 to August 16, 2031, allowing use in China and other countries recognizing NMPA.

    Source: